Please select CHADSVASC and HASBLED risk factors, EHRA score and click copy to clipboard to copy and paste in your electronic files
Chadsvasc risk factors [click on present risk factors]
RISK FACTORS
|
SCORE |
Congestive heart failure
congestive_heart_failure
|
1 |
Hypertension
Hypertension
|
1 |
Age ≥ 75
Age ≥ 75
|
2 |
Age 65-74
Age ≥ 75
|
1 |
Diabetes mellitus
Diabetes mellitus
|
1 |
Stroke/TIA/thrombo-embolism
Stroke/TIA/thrombo-embolism
|
2 |
Vascular disease
Vascular disease
|
1 |
|
Sex Female
Sex Female
|
1 |
Your score |
0 |
CHADSVASC clinical risk estimation. Adapted from Lip et al. See Van den Ham et al. below for actual risks in a larger population.
CHA2DS2VASc SCORE |
PATIENTS (n=7329) |
ADJUSTED STROKE RATE (% year) |
0 |
1 |
0% |
1 |
422 |
1,3% |
2 |
1230 |
2,2% |
3 |
1730 |
3,2% |
4 |
1718 |
4,0% |
5 |
1159 |
6,7% |
6 |
679 |
9,8% |
7 |
294 |
9,6% |
8 |
82 |
6,7% |
9 |
14 |
15,2% |
HASBLED clinical characteristic [click on present risk factors]
CLINICAL CHARACTERISTIC |
POINTS AWARDED |
Hypertension
Hypertension
|
1 |
Abnormal liver function
Abnormal liver function
|
1 |
Abnormal renal function
Abnormal renal function
|
1 |
Stroke
Stroke
|
1 |
Bleeding
Bleeding
|
1 |
Labile INRs
Labile INRs
|
1 |
Elderly (Age >65)
Elderly (e.g. >65)
|
1 |
Drugs
Drugs
|
1 |
Alcohol
Alcohol
|
1 |
Your score |
0 |
HASBLED clinical risk estimation. Adapted from Pisters et al.
HAS BLED SCORE |
NUMBER OF PATIENTS |
NUMBER OF BLEEDING |
BLEEDS PER 100 PATIENT YEARS |
0 |
798 |
9 |
1,13 |
1 |
1286 |
13 |
1,02 |
2 |
744 |
14 |
1,88 |
3 |
187 |
7 |
3,74 |
4 |
46 |
4 |
8,70 |
5 |
8 |
1 |
12,50 |
6 |
2 |
0 |
0 |
7 |
--- |
--- |
--- |
8 |
--- |
--- |
--- |
9 |
--- |
--- |
--- |
Total |
798 |
9 |
1,13 |
Classificaton of AF-related symptoms (EHRA score)
EHRA I
|
No symptoms |
EHRA II
Mild symptoms; normal daily activity not affected
|
Mild symptoms; normal daily activity not affected |
EHRA III
Severe symptoms; normal daily activity affected
|
Severe symptoms; normal daily activity affected |
EHRA IV
Disabling symptoms; normal daily activity discontinued
|
Disabling symptoms; normal daily activity discontinued |
CHA2DS2-VASc=not filled in, HASBLED=not filled in
copy to clipboard
copied to clipboard
cha2ds2-vasc=not filled in, hasbled=not filled in
copy to clipboard
copied to clipboard
cha2ds2-vasc=not filled in, hasbled=not filled in
copy to clipboard
copied to clipboard
| Haemorrhagic risk | Stroke risk | Clinical setting | Recommendations according to EHRA / ESC / EAPCI 2014 consensus document |
|---|---|---|---|
| Low or moderate (HAS-BLED 0-2) |
Moderate (CHA2DS2-VASC = 1 in males) |
Stable CAD |
At least 4 weeks (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
| High (CHA2DS2-VASC ≥2) |
Stable CAD |
At least 4 weeks (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day<
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| Moderate (CHA2DS2-VASC = 1 in males) |
ACS |
6 months: triple therapy of OAC + aspirin 75-100 mg/day +
clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| High (CHA2DS2-VASC ≥2) |
ACS |
6 months: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively,
aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| High (HAS-BLED ≥3) |
Moderate (CHA2DS2-VASC = 1 in males) |
Stable CAD |
Up to 12th month: OAC and clopidogrel 75 mg/day
Lifelong: OAC
|
| High (CHA2DS2-VASC ≥2) |
Stable CAD |
4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| Moderate (CHA2DS2-VASC = 1 in males) |
ACS |
4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/dayd
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|
|
| High (CHA2DS2-VASC ≥2) |
ACS |
4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/dayd
Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day)
Lifelong: OAC
|